Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Bausch + Lomb Corp

Healthcare US BLCO

15.2USD
0.27(1.81%)

Last update at 2026-06-23T18:31:00Z

Day Range

14.8615.27
LowHigh

52 Week Range

10.4518.91
LowHigh

Fundamentals

  • Previous Close 14.93
  • Market Cap5716.38M
  • Volume163384
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA609.00M
  • Revenue TTM5101.00M
  • Revenue Per Share TTM14.42
  • Gross Profit TTM 3051.00M
  • Diluted EPS TTM-1.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -317.00000M -234.00000M -166.00000M 73.00M 318.00M
Minority interest -8.00000M -12.00000M -12.00000M 9.00M -11.00000M
Net income -360.00000M -317.00000M -260.00000M 15.00M 182.00M
Selling general administrative 2234.00M 1554.00M 1361.00M 1478.00M 1389.00M
Selling and marketing expenses - 528.00M 375.00M - -
Gross profit 2995.00M 2919.00M 2504.00M 2249.00M 2298.00M
Reconciled depreciation 421.00M 436.00M 382.00M 379.00M 415.00M
Ebit 151.00M 165.00M 117.00M 207.00M 329.00M
Ebitda 572.00M 601.00M 499.00M 457.00M 785.00M
Depreciation and amortization 421.00M 436.00M 382.00M 250.00M 456.00M
Non operating income net other - - - 12.00M -
Operating income 159.00M 162.00M 130.00M 207.00M 329.00M
Other operating expenses 4942.00M 4629.00M 4016.00M 3548.00M 3419.00M
Interest expense 431.00M 399.00M 283.00M 146.00M 63.00M
Tax provision 35.00M 71.00M 82.00M 58.00M 125.00M
Interest income 12.00M 15.00M 15.00M 6.00M 0.00000M
Net interest income -409.00000M -384.00000M -268.00000M -140.00000M 0.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 35.00M 71.00M 82.00M 58.00M 125.00M
Total revenue 5101.00M 4791.00M 4146.00M 3768.00M 3765.00M
Total operating expenses 2836.00M 2757.00M 2374.00M 2029.00M 1952.00M
Cost of revenue 2106.00M 1872.00M 1642.00M 1519.00M 1467.00M
Total other income expense net -476.00000M -396.00000M -296.00000M -134.00000M -11.00000M
Discontinued operations - - - - -
Net income from continuing ops -352.00000M -305.00000M -248.00000M 15.00M 193.00M
Net income applicable to common shares - - - 6.00M 182.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 14022.00M 13469.00M 13442.00M 11144.00M 10823.00M
Intangible assets 3281.00M 3494.00M 3589.00M 2058.00M 2264.00M
Earning assets - - - - -
Other current assets 397.00M 421.00M 541.00M 431.00M 165.00M
Total liab 7503.00M 6925.00M 6522.00M 4043.00M 1421.00M
Total stockholder equity 6448.00M 6473.00M 6850.00M 7033.00M 9329.00M
Deferred long term liab - - - 7.00M -
Other current liab 1455.00M 1277.00M 400.00M 901.00M 860.00M
Common stock - - - - 10364.00M
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 10364.00M
Retained earnings -931.00000M -571.00000M -254.00000M 6.00M -
Other liab - - - 244.00M 230.00M
Good will 4758.00M 4523.00M 4575.00M 4507.00M 4586.00M
Other assets - - - 1023.00M 1001.00M
Cash 383.00M 305.00M 331.00M 354.00M 174.00M
Cash and equivalents - - - - -
Total current liabilities 1920.00M 1738.00M 1579.00M 1296.00M 1099.00M
Current deferred revenue - - 627.00M - -
Net debt 4987.00M 4631.00M 4231.00M 2082.00M -174.00000M
Short term debt 77.00M 72.00M 30.00M 25.00M -
Short long term debt 39.00M 40.00M 30.00M 25.00M -
Short long term debt total 5370.00M 4936.00M 4562.00M 2436.00M -
Other stockholder equity 8563.00M 8429.00M 8349.00M 8285.00M -1035.00000M
Property plant equipment - - - 1300.00M 1337.00M
Total current assets 2977.00M 2788.00M 2742.00M 2137.00M 1635.00M
Long term investments - - - - -
Net tangible assets - - - 468.00M 2479.00M
Short term investments - - - - -
Net receivables 1221.00M 1026.00M 839.00M 724.00M 721.00M
Long term debt 5043.00M 4744.00M 4532.00M 2411.00M -
Inventory 976.00M 1036.00M 1028.00M 628.00M 572.00M
Accounts payable 388.00M 389.00M 522.00M 370.00M 239.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 68.00M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1184.00000M -1385.00000M -1245.00000M -1258.00000M -1035.00000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - 6.00M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 303.00M 275.00M 206.00M 215.00M 180.00M
Deferred long term asset charges - - - - -
Non current assets total 11045.00M 10681.00M 10700.00M 9007.00M 9188.00M
Capital lease obligations - - - - -
Long term debt total - - - 2411.00M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -3.00000M -412.00000M -2064.00000M -40.00000M -5.00000M
Change to liabilities - - - 189.00M 163.00M
Total cashflows from investing activities -455.00000M -412.00000M -2109.00000M -215.00000M -214.00000M
Net borrowings 261.00M 201.00M 2115.00M 2424.00M 28.00M
Total cash from financing activities 225.00M 178.00M 2078.00M 81.00M -712.00000M
Change to operating activities - - - -7.00000M -13.00000M
Net income -352.00000M -305.00000M -248.00000M 15.00M 193.00M
Change in cash 81.00M -18.00000M -46.00000M 203.00M -61.00000M
Begin period cash flow 316.00M 334.00M 380.00M 177.00M 238.00M
End period cash flow 397.00M 316.00M 334.00M 380.00M 177.00M
Total cash from operating activities 283.00M 232.00M -17.00000M 345.00M 873.00M
Issuance of capital stock - - - - -
Depreciation 421.00M 436.00M 382.00M 379.00M 415.00M
Other cashflows from investing activities -103.00000M -123.00000M 14.00M - -
Dividends paid - - - - -
Change to inventory 38.00M -147.00000M -264.00000M -106.00000M -15.00000M
Change to account receivables -148.00000M -227.00000M -121.00000M -95.00000M -107.00000M
Sale purchase of stock - -12.00000M -10.00000M -11.00000M -
Other cashflows from financing activities -24.00000M -11.00000M -37.00000M 94.00M -712.00000M
Change to netincome - - - -57.00000M 248.00M
Capital expenditures 349.00M 291.00M 181.00M 175.00M 209.00M
Change receivables - - - -95.00000M -
Cash flows other operating - - - 12.00M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 211.00M -
Change in working capital 18.00M -87.00000M -287.00000M -19.00000M 28.00M
Stock based compensation 149.00M 92.00M 74.00M 62.00M 62.00M
Other non cash items 79.00M 106.00M 72.00M -2.00000M 59.00M
Free cash flow -66.00000M -59.00000M -198.00000M 170.00M 664.00M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BLCO
Bausch + Lomb Corp		 0.27 1.81% 15.20 - 15.55 1.12 0.93 2.08 20.25
ISRG
Intuitive Surgical Inc		 0.23 0.06% 403.18 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme		 - -% 192.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -0.67 0.70% 95.69 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 3.21 2.28% 143.92 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

View All

Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Corp

520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4

Key Executives

Name Title Year Born
Mr. Joseph C. Papa CEO & Director 1956
Mr. Osama A. Eldessouky Exec. VP & CFO 1972
Ms. Christina M. Ackermann Exec. VP, Gen. Counsel & Pres of Ophthalmic Pharmaceuticals 1965
Mr. Joseph F. Gordon Pres of Global Consumer, Surgical & Vision Care 1965
Ms. Kelly Webber Exec. VP & Chief HR Officer NA
Dr. Yehia Hashad M.D. Exec. VP of R&D and Chief Medical officer 1967
Mr. Louis W. Yu Exec. VP & Chief Quality Officer 1950
Mr. Dennis Asharin Exec. VP and Chief Global Manufacturing & Supply Chain Officer NA
Mr. Osama A. Eldessouky Executive VP & CFO 1972
Dr. Yehia Hashad M.D. Executive VP of Research & Development and Chief Medical officer 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.